PDCD1 and neoplasm: For PD-1 inhibitor-refractory patients who did not respond initially, infusion of fecal microbiota from responders (e.g., in trial NCT03341143) could reshape the gut microbiota and reverse the immunosuppressive tumor microenvironment in a subset of patients (approximately 40%), thereby overcoming drug resistance (56).